Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 1414

1.

Factor XI and Contact Activation as Targets for Antithrombotic Therapy.

Gailani D, Bane CE, Gruber A.

J Thromb Haemost. 2015 May 14. doi: 10.1111/jth.13005. [Epub ahead of print]

PMID:
25976012
2.

Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone on risk of recurrent pulmonary embolism: a randomized clinical trial.

Mismetti P, Laporte S, Pellerin O, Ennezat PV, Couturaud F, Elias A, Falvo N, Meneveau N, Quere I, Roy PM, Sanchez O, Schmidt J, Seinturier C, Sevestre MA, Beregi JP, Tardy B, Lacroix P, Presles E, Leizorovicz A, Decousus H, Barral FG, Meyer G; PREPIC2 Study Group.

JAMA. 2015 Apr 28;313(16):1627-35. doi: 10.1001/jama.2015.3780.

PMID:
25919526
3.

[Fondaparinux -- mechanism of action, and effective and broad range of indications].

Bauersachs RM.

Vasa. 2015 Mar;44(2):138-9. German. No abstract available.

PMID:
25881373
4.

Dabigatran for the prevention and treatment of thromboembolic disorders.

Enriquez A, Baranchuk A, Redfearn D, Simpson C, Abdollah H, Michael K.

Expert Rev Cardiovasc Ther. 2015 May;13(5):529-40. doi: 10.1586/14779072.2015.1034692. Epub 2015 Apr 5.

PMID:
25843430
5.

[New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].

Oberhofer E.

MMW Fortschr Med. 2015 Jan 19;157(1):24. German. No abstract available.

PMID:
25743289
6.

Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism.

Bacchus F, Schulman S.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):513-9. doi: 10.1161/ATVBAHA.114.303396. Epub 2014 Aug 14.

PMID:
25717178
7.

Practical guidelines for venous thromboembolism chemoprophylaxis in elective plastic surgery.

Iorio ML, Venturi ML, Davison SP.

Plast Reconstr Surg. 2015 Feb;135(2):413-23. doi: 10.1097/PRS.0000000000000908.

PMID:
25626788
8.

Postoperative prophylaxis of venous thromboembolism (VTE) in patients undergoing high ligation and stripping of the great saphenous vein (GSV).

Wang H, Sun Z, Jiang W, Zhang Y, Li X, Wu Y.

Vasc Med. 2015 Apr;20(2):117-21. doi: 10.1177/1358863X14564592. Epub 2015 Jan 19.

PMID:
25601917
9.

Is prophylactic anticoagulation for deep venous thrombosis common practice after intracerebral hemorrhage?

Prabhakaran S, Herbers P, Khoury J, Adeoye O, Khatri P, Ferioli S, Kleindorfer DO.

Stroke. 2015 Feb;46(2):369-75. doi: 10.1161/STROKEAHA.114.008006. Epub 2015 Jan 8.

PMID:
25572413
10.

Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory.

Blann AD.

Br J Biomed Sci. 2014;71(4):158-67. Review.

PMID:
25562993
11.

D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study.

Kearon C, Spencer FA, O'Keeffe D, Parpia S, Schulman S, Baglin T, Stevens SM, Kaatz S, Bauer KA, Douketis JD, Lentz SR, Kessler CM, Moll S, Connors JM, Ginsberg JS, Spadafora L, Julian JA; D-dimer Optimal Duration Study Investigators.

Ann Intern Med. 2015 Jan 6;162(1):27-34. doi: 10.7326/M14-1275.

PMID:
25560712
12.

Tranexamic acid--an old drug still going strong and making a revival.

Tengborn L, Blombäck M, Berntorp E.

Thromb Res. 2015 Feb;135(2):231-42. doi: 10.1016/j.thromres.2014.11.012. Epub 2014 Nov 20. Review.

PMID:
25559460
13.

[Advantages and disadvantages of warfarin and pradaxa therapy for venous thromboembolism].

Sukovatykh BS, Belikov LN, Savchuk OF, Sukovatykh MB.

Vestn Khir Im I I Grek. 2014;173(4):87-91. Russian.

PMID:
25552114
14.

A meta-analysis of randomized controlled trials of the risk of bleeding with apixaban versus vitamin K antagonists.

Touma L, Filion KB, Atallah R, Eberg M, Eisenberg MJ.

Am J Cardiol. 2015 Feb 15;115(4):533-41. doi: 10.1016/j.amjcard.2014.11.039. Epub 2014 Dec 2. Review.

PMID:
25547937
15.

Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

Pathak R, Pandit A, Karmacharya P, Aryal MR, Ghimire S, Poudel DR, Shamoun FE.

Am J Cardiol. 2015 Feb 1;115(3):323-7. doi: 10.1016/j.amjcard.2014.10.042. Epub 2014 Nov 13.

PMID:
25527282
16.

The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.

Sengupta N, Feuerstein JD, Patwardhan VR, Tapper EB, Ketwaroo GA, Thaker AM, Leffler DA.

Am J Gastroenterol. 2015 Feb;110(2):328-35. doi: 10.1038/ajg.2014.398. Epub 2014 Dec 16. Erratum in: Am J Gastroenterol. 2015 Mar;110(3):480.

PMID:
25512338
17.

Treatment patterns and outcomes among hospitalized patients with venous thromboembolism in the United States: an analysis of electronic health records data.

Menzin J, Preblick R, Friedman M, Menzin J, Frean M, Jacqueline Kwong W.

Hosp Pract (1995). 2014 Oct;42(4):59-74. doi: 10.3810/hp.2014.10.1143.

PMID:
25502130
18.

Parenteral anticoagulation in ambulatory patients with cancer.

Akl EA, Kahale LA, Ballout RA, Barba M, Yosuico VE, van Doormaal FF, Middeldorp S, Bryant A, Sch√ľnemann H.

Cochrane Database Syst Rev. 2014 Dec 10;12:CD006652. doi: 10.1002/14651858.CD006652.pub4. Review.

PMID:
25491949
19.

[Laboratory assessment of haemostatic parameters in patients taking a direct thrombin inhibitor].

Beliavskaia OO, Vavilova TV.

Angiol Sosud Khir. 2014;20(4):37-41. Russian.

PMID:
25490355
20.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk